Summary: Eight patients were treated with two 80-mg.
Introduction
Methylprednisolone acetate (Depo-Medrone), a slow-release steroid for injection, is used in the treatment of allergic and other disorders but no information is available to indicate the effect of this treatment on the hypothalamicpituitary-adrenal axis. It seemed desirable, therefore, to assess hypothalamic-pituitary-adrenal function in a group of patients receiving methylprednisolone acetate in the dosage used for a recent trial of hay-fever treatment (Ganderton, Brostoff, and Frankland, 1969) , when two 80-mg. injections of methylprednisolone acetate were given at an interval of two weeks. The effect on the resting plasma cortisol level, on the response of the adrenal gland to synthetic adrenocorticotrophic hormone (Synacthen), and on the plasma cortisol response to the stress of insulin-induced hypoglycaemia was studied.
Scheme and Method of Trial During the spring of 1968 the purpose and requirements of our study were explained to patients for whom treatment with intramuscular methylprednisolone appeared suitable, and volunteers were selected from those who worked near St. Mary's Hospital and were willing to attend for repeated investigations. Eight patients were studied: six suffered from seasonal hay-fever and had presented too late for preseasonal hyposensitization, one suffered from intrinsic asthma, and one from urticaria. All except the asthmatic patient were outpatients. (Townsend and James, 1968) . The specificity of this method for the estimation of plasma cortisol has been discussed by James, Townsend, and Fraser (1967) .
Though availability of patients determined the time at which blood samples could be taken, all resting samples from any one patient were taken at the same time, the patient thereby acting as his own control.
In six patients hypothalamic-pituitary-adrenal function was assessed by measuring the adrenal response to the stress of hypoglycaemia (Greenwood, Landon, and Stamp, 1966) . This was done about one week after the adrenal response to corticotrophin had returned to normal.
Results
Effects on Resting Plasma Cortisol.- Fig. 1 shows the resting plasma cortisol levels as means of three-day periods for the group of patients studied. There was a sharp fall immediately after the first dose of methylprednisolone, with subsequent recovery towards the mean pretreatment level of 11
Mug./100 ml. plasma. Before full recovery had occurred, the second dose of methylprednisolone again produced a depression of the plasma cortisol, which was more pronounced than the previous fall. By day 17 the mean level was 2-7 ,ug./100 ml. plasma. The resting levels then slowly increased, though by day 30 they had not achieved the pretreatment level. The results for two individual patients (Cases 1 and 2) are shown in detail in Figs. 2 A and B, while Fig. 3 shows the variations occurring between individual patients.
Response to Corticotrophin.-Adrenocortical responsiveness to corticotrophin was measured at intervals throughout the treatment; the results are shown in Fig. 4 . There was a decrease in adrenal response to corticotrophin which was very pronounced immediately after the second dose of methylprednisolone with subsequent recovery towards normal. By day 38-that is, three weeks after the second dose-the mean response had not quite reached normality, as defined by the criteria stated above, a mean stimulated value of 20,ug./100 ml. not being reached until day 45. One patient still showed some degree of adrenal depression on day 45, reaching a maximum Hay-fever-Ganderton and James 11 . some patients were studied for as long as 60 days after treatment was started, none of them in this period achieved adrenal responses as high as those seen before treatment.
Response to Hypoglycaemia.-The adrenocortical responses of six patients to insulin-induced hypoglycaemia are shown in Fig. 5 . These tests were withheld until the results of the patient's corticotrophin test were within normal limits. The insulin tests showed normal responsiveness in all except Case 6, who still showed some minor degree of suppression of hypothalamic-pituitary-adrenal function as late as 85 days after beginning treatment.
Discussion
Although the dynamics of steroid absorption after intramuscular and oral administration are undoubtedly different, it appears that the effects on pituitary-adrenal function are broadly similar. Plasma cortisol levels were maximally depressed for 72 hours after the injection of methylprednisolone, presumably while steroid release from the injection site occurred, and then returned towards initial levels. As would be (Fig. 2 A) showed profound depression of plasma cortisol levels, while levels in Case 2 (Fig. 2 B) rapidly returned to normal. Though only one patient (Case 2) had a pretreatment level of less than 5 ,ug./100 ml., the time taken to recover a resting level of 5 ,ug./100 ml. varied from 6 to 30 days after the second injection.
It was impossible to predict the type of endocrine response from a patient's physical appearance, age, sex, or initial response to corticotrophin; contrary to widely held belief, the degree of adrenal suppression did not necessarily correlate with clinical improvement. Thus two of our patients continued to have symptoms despite evidence of adrenal suppression, while two reported good clinical improvement though their plasma cortisol levels were only slightly lowered. It should not be assumed that there is no suppression of pituitary-adrenal function because asthma has not been relieved. Unless regular plasma cortisol estimations are performed it is impossible to identify the occasional patient who manifests pronounced adrenal suppression and may therefore be at risk in the case of illness or accident. Such tests are beyond the scope of routine practice.
Clinically our patients fared worse than the larger group studied in the previous trial (Ganderton et al., 1969) , where 70'%'0 of patients treated with methylprednisolone acetate were improved, and only 2% reported that they had developed asthma for the first time. Three of our six hay-fever patients were improved, but three developed asthma for the first time during the summer. As the asthma appeared two to three weeks after the second injection of methylprednisolone acetate, there would be the temptation to administer further doses to this type of patient. As indicated above, such continuing treatment could well produce more pronounced hypothalamic-pituitary-adrenal suppression.
Several conditions which may have been side-effects of steroid treatment were encountered. One patient reported a severe exacerbation of peptic ulcer symptoms; another developed severe cramps which eased when potassium supplements were administered, and this patient also suffered a recurrence of infantile eczema, which had not troubled him since the age of 2 years. A third patient subsequently developed an anterior uveitis of unknown origin, and this may have resulted from reactivation of an old tuberculous lesion. The incidence of clinical complications and of side-effects which may have been due to steroid treatment was much higher in this small series than one would expect. This may be due to the error in sampling encountered in a small series, but it could also be argued that the information was obtained because patients were interviewed carefully at very frequent intervals.
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